Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 4/20 | 0.38 |
| ▸ | CDK9 | P50750 | 3/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.32 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.32 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4928912 | 0.81 | HRH3 (0.34) | — | |
| SCHEMBL4240983 | 0.81 | WDR5 (0.35) | NTRK1 | |
| SCHEMBL4932373 | 0.80 | HRH3 (0.35) | — | |
| SCHEMBL4243728 | 0.80 | PPARG (0.40) | NTRK1 | |
| SCHEMBL4243737 | 0.79 | PDE5A (0.35) | — | |
| SCHEMBL4245052 | 0.79 | MEN1 (0.40) | — | |
| SCHEMBL4240290 | 0.79 | HPGD (0.40) | — | |
| SCHEMBL4245040 | 0.78 | NPC1 (0.32) | — | |
| SCHEMBL4246201 | 0.78 | CDK9 (0.36) | CDK9 | |
| SCHEMBL4247402 | 0.78 | ITGB3 (0.36) | NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099155-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ARRAY BIOPHARMA, INC. | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099155-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | HTR2C, HTR5A, HTR4 | CCNT1 2560/4885CDK9 2900/4885ADORA2B 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.